United Therapeutics (NASDAQ:UTHR) Price Target Raised to $705.00 at UBS Group

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by UBS Group from $655.00 to $705.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other reports. Royal Bank Of Canada raised their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, TD Cowen lifted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $539.00.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $485.06 on Thursday. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $537.19. The company has a market capitalization of $21.26 billion, a P/E ratio of 17.39, a P/E/G ratio of 1.77 and a beta of 0.84. The company has a 50 day simple moving average of $483.09 and a 200-day simple moving average of $451.14.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the business posted $6.19 earnings per share. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics will post 24.48 EPS for the current year.

Insider Buying and Selling

In other news, Director Christopher Causey sold 1,000 shares of United Therapeutics stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total transaction of $520,000.00. Following the completion of the sale, the director directly owned 4,190 shares of the company’s stock, valued at approximately $2,178,800. The trade was a 19.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $63,688.30. The trade was a 98.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 377,184 shares of company stock worth $183,015,947 over the last ninety days. Company insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. lifted its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of United Therapeutics by 12.6% during the second quarter. Atria Investments Inc now owns 945 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 106 shares during the period. Resona Asset Management Co. Ltd. boosted its holdings in shares of United Therapeutics by 7.5% in the second quarter. Resona Asset Management Co. Ltd. now owns 21,840 shares of the biotechnology company’s stock valued at $6,271,000 after acquiring an additional 1,521 shares in the last quarter. Andra AP fonden boosted its holdings in United Therapeutics by 16.0% in the 2nd quarter. Andra AP fonden now owns 118,400 shares of the biotechnology company’s stock valued at $34,022,000 after purchasing an additional 16,300 shares in the last quarter. Finally, Savant Capital LLC grew its holdings in United Therapeutics by 1.8% during the second quarter. Savant Capital LLC now owns 10,042 shares of the biotechnology company’s stock worth $2,886,000 after acquiring an additional 182 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating, implying sizable upside versus recent levels; analyst enthusiasm can support the stock. UBS raises price target
• Positive Sentiment: Late‑stage trial news: United Therapeutics reported a drug slowed progression of a rare lung condition in a late‑stage study — clinical efficacy data like this strengthens the company’s pipeline outlook and long‑term revenue prospects. Late-stage study report
• Neutral Sentiment: Director Christopher Causey disclosed a small sale (20 shares) on March 4; the size is immaterial relative to his holding and likely not a market signal. Causey SEC filing
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (disclosed March 4), a large reduction in her position; sizable insider sales by the CEO can spook investors and contribute to downward pressure on the stock. Rothblatt SEC filing
• Negative Sentiment: Director Tommy G. Thompson sold 2,000 shares (March 4), reducing his stake by ~19%; another notable insider sale that may amplify concerns. Thompson SEC filing
• Negative Sentiment: Director Ray Kurzweil sold 4,910 shares (March 4), a ~28% reduction in his holding; cumulative insider selling from multiple senior figures raises liquidity/optics concerns for some investors. Kurzweil SEC filing
• Negative Sentiment: EVP Paul A. Mahon sold 8,300 shares on March 5, an ~18% reduction in his stake; this is another large insider sale disclosed this week. Mahon SEC filing

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.